Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Our data indicate that FN1 may serve as a potential therapeutic target to address TKI resistance or as a suitable biomarker for the treatment.
Authors
- Inga Nagel (ORCID: https://orcid.org/0000-0001-5174-4454)
- Vicki Waetzig (ORCID: https://orcid.org/0000-0001-6690-5281)
- Merit Litterst
- Johanna Ruemenapp
- Ingolf Cascorbi (ORCID: https://orcid.org/0000-0002-2182-9534)
- Nikolas C. C. von Bubnoff (ORCID: https://orcid.org/0000-0001-9593-8947)
- Luisa Schmidt (ORCID: https://orcid.org/0000-0002-5181-9927)
- Meike Kaehler (ORCID: https://orcid.org/0000-0002-2401-6037)
- Sivahari Prasad Gorantla (ORCID: https://orcid.org/0009-0001-2977-3870)
- Christiane Pott (ORCID: https://orcid.org/0009-0005-9260-8340)
- Lina Tiedemann
- Philine Ahlf
Institutions
- University Hospital Schleswig-Holstein (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.3389/fcell.2025.1725857
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft